The ATHJF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATHJF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATHJF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ATHJF Detailed Price Forecast - CNN Money||View ATHJF Detailed Summary - Google Finance|
|View ATHJF Detailed Summary - Yahoo! Finance||View ATHJF Stock Research & Analysis - Zacks.com|
|View ATHJF Trends & Analysis - Trade-Ideas||View ATHJF Major Holders - Barrons|
|View ATHJF Call Transcripts - NASDAQ||View ATHJF Breaking News & Analysis - Seeking Alpha|
|View ATHJF Annual Report - CompanySpotlight.com||View ATHJF OTC Short Report - OTCShortReport.com|
|View ATHJF Fundamentals - TradeKing||View ATHJF SEC Filings - Bar Chart|
|View Historical Prices for ATHJF - The WSJ||View Performance/Total Return for ATHJF - Morningstar|
|View the Analyst Estimates for ATHJF - MarketWatch||View the Earnings History for ATHJF - CNBC|
|View the ATHJF Earnings - StockMarketWatch||View ATHJF Buy or Sell Recommendations - MacroAxis|
|View the ATHJF Bullish Patterns - American Bulls||View ATHJF Short Pain Metrics - ShortPainBot.com|
|View ATHJF Stock Mentions - StockTwits||View ATHJF Stock Mentions - PennyStockTweets|
|View ATHJF Stock Mentions - Twitter||View ATHJF Investment Forum News - Investor Hub|
|View ATHJF Stock Mentions - Yahoo! Message Board||View ATHJF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ATHJF - SECform4.com||View Insider Transactions for ATHJF - Insider Cow|
|View ATHJF Major Holdings Summary - CNBC||View Insider Disclosure for ATHJF - OTC Markets|
|View Insider Transactions for ATHJF - Yahoo! Finance||View Institutional Holdings for ATHJF - NASDAQ|
|View ATHJF Stock Insight & Charts - FinViz.com||View ATHJF Investment Charts - StockCharts.com|
|View ATHJF Stock Overview & Charts - BarChart||View ATHJF User Generated Charts - Trading View|
What Kind Of Shareholder Appears On The Antisense Therapeutics Limited’s (ASX:ANP) Shareholder Register?
Posted on Sunday October 28, 2018
Every investor in Antisense Therapeutics Limited (ASX:ANP) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often
ATL1103 Phase II trial results published in the European Journal of Endocrinology
Posted on Thursday May 24, 2018
MELBOURNE, Australia, May 24, 2018 /PRNewswire/ -- Antisense Therapeutics (the "Company" or "ANP") is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-reviewed medical journal, the European Journal of Endocrinology. An abstract of the article, titled 'A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly,' is currently available online http://dx.doi.org/10.1530/EJE-18-0138 with the full manuscript to be included in a future print edition and anticipated to be made available free on line in due course. The article highlights the successful outcomes of the Phase II clinical trial of ATL1103 in acromegaly patients where the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in 26 adult acromegaly patients dosed with ATL1103 for 13 weeks were assessed.
ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology
Posted on Wednesday May 23, 2018
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication ...
Approval Received for Phase II Trial of ATL1102 in Duchenne Muscular Dystrophy
Posted on Wednesday February 28, 2018
MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received ...